Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Adenocarcinoma × nimotuzumab × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Neoplasm Metastasis 1 Esophageal Neoplasms 1 Adenocarcinoma 1

Interventions

Oxaliplatin 2 Fluorouracil 2 rubitecan 1 nimotuzumab 1 halofantrine 1 gallium 68 PSMA-11 1 camrelizumab 1 apatinib 1 S 1 (combination) 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 Photochemotherapy 1 Nadroparin 1 Heparin, Low-Molecular-Weight 1 Gastrectomy 1 Esophagectomy 1 Docetaxel 1 Cisplatin 1 Chemoradiotherapy 1 Capecitabine 1 CP protocol 1 Brachytherapy 1 Atrasentan 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡